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Aim: The purpose of our review was to evaluate results of radiosurgery for patients with
brain metastases from lung cancer.
Background: Lung cancer is the leading cause of death from cancer and the most common
source of brain metastases. Radiosurgery allows the precise focal delivery of a high single
radiation dose to brain metastases and results in high rates of local control.
Materials and methods: 83 patients were treated between 2006 and 2008. We  evaluated local
control and outcome after radiosurgery and identiﬁed prognostic factors.
Results: Median survival in the whole group was 7.8 months from radiosurgery and 11 months
from diagnosis. Median survival in classes I, II and III was 13.2, 8.2 and 2.2 months. For 94%
of  patients symptoms improved or stabilised at the ﬁrst follow-up visit and this status did
not  change during 7.1 months. According to the univariate analysis, factors associated with
improved survival included: RPA class 1 compared with RPA 2 and 3, RPA class 2 compared
with RPA 3, KPS > 70, control of the primary disease, radiosurgery performed more than once,
level  of haemoglobin >7 mmol/1, absence of extracranial metastases, volume of the biggest
lesion <11 cm3. The multivariate analysis conﬁrmed a signiﬁcant inﬂuence on survival for
the  following factors: RPA class 1 as compared with RPA 3, KPS > 70, absence of extracranial
metastases, multiplicity of radiosurgery.
Conclusions: Stereotactic radiosurgery is a safe and effective treatment. It proved to be effec-
tive  and safe in older patients. Selection of patients who are likely to beneﬁt most shouldbe  based on prognostic factors. KPS proved to be the most important prognostic factor. In
the  RPA III group (patients with KPS < 70) survival time was similar to that achieved after
symptomatic medical management.
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lung cancer are still unsatisfactory. This is due to the fact that© 2013 Greater Pol
.  Introductionung cancer is currently the most prevalent malignancy in
he world, accounting for 34% of all cancer deaths. It is also
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the most prevalent cancer in Poland. Treatment results forthe disease is usually diagnosed at later stages, with 70% of
patients with locally advanced or metastatic cancer. There-
fore, a large proportion of patients are not eligible for radical
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Table 1 – Prognostic factors by RPA classes.
RPA classes Mean survival
in months
RPA class I
KPS ≥ 70, age < 65, primary disease controlled,
no extracranial metastases
7.1
RPA class II
KPS ≥ 70 and at least one of the following:
age≥65, uncontrolled primary disease,
extracranial metastases
4.2
radiosurgery over traditional methods of radiation lies inRPA class III
KPS < 70 2.3
therapy and are given palliative treatment instead. Such treat-
ment is aimed to improve their quality of life by mitigating
pain and to prolong survival. The ﬁve-year survival rate with
such patients is only around 10%. In patients with stage IV
(metastatic) non-small cell lung cancer, the ﬁve-year survival
rate is below 5%. In extensive disease small cell lung can-
cer, it is merely 1–2%. Brain metastases develop in 30% of all
non-small cell lung cancer patients.1 In approximately 10% of
SCLC patients, metastases to the central nervous system are
found at diagnosis.2 As the disease progresses, brain metas-
tases occur more  often (in 60–80% of patients with two-year
survival). Of all cases of brain metastases, those from lung
cancer represent 40–50%. Brain metastases have a strong neg-
ative impact on prognosis and quality of life. It usually requires
urgent treatment. The most important aim of such treatment
is to improve neurological performance and prolong survival.
The choice of a therapeutic method is based on individual
assessment of prognostic factors.
Modern brain metastases therapy is based on individ-
ual assessment of prognostic factors.3,4 These include: age,
general status as Karnofsky performance scale, type of pri-
mary tumour, number of brain metastases (single or multiple)
and progression of extracranial processes. The analysis of
those factors based on three clinical trials conducted by the
RTOG (1200 patients) allowed to distinguish three prognostic
classes.5 Gaspar3 used the RTOG database to perform a recur-
sive partitioning analysis (RPA). The Karnofsky performance
status proved to be the most signiﬁcant prognostic factor in
an univariate analysis. Among patients with KPS 70 or lower,
the primary tumour status was the second key prognostic
factor, preceding age and extracranial metastases. Three pro-
gnostic classes were distinguished: RPA class I consisted of
patients with KPS > 70 and higher, aged 65 or younger with
controlled primary cancer and no extracranial metastases,
whose mean survival period was 7.1 months. RPA class II
consisted of patients who  had not been qualiﬁed into classes
I or III (with KPS > 70 and met  one of the following crite-
ria: age > 65, uncontrolled primary disease or presence of
extracranial metastases). Mean survival time in class II was
4.2 months. Class III covered patients with performance status
<70, mean survival time in that class was 2.3 months.
Prognostic factors by RPA classes are shown in Table 1.
The RPA classiﬁcation may be used to select a smallgroup of patients for radical local treatment (surgery, radio-
surgery). There are several important prognostic factors which
are not included in the RPA classiﬁcation. All prognosticdiotherapy 1 9 ( 2 0 1 4 ) 19–29
factors should be taken into account while selecting a treat-
ment method. Very intensive treatment methods should be
considered for patients with favourable prognostic factors,
while less intensive or symptomatic treatment for those with
unfavourable prognosis. Quality of life, alongside with the
length of life, is an important aspect for assessment of treat-
ment efﬁcacy (particularly in the context of short survival time
of brain metastases patients).
Considering a small number of Polish studies concern-
ing prognostic factors in brain metastases radiosurgery, we
decided to base this evaluation on treatment results for
patients with brain metastases from lung cancer treated with
radiosurgery in the period from February 2006 to September
2008.
2.  Radiosurgery
Radiosurgery is performed with a so-called gamma knife or
with the aid of a linear accelerator (LINAC). This method, in
contrast to conventional radiation therapy, involves a one-
off delivery of high-dose irradiation to a strictly limited
area in order destroy it, wherein it resembles a surgical
procedure (hence the name radiosurgery). In radiobiological
terms, a delivery of a single high dose prevents a repair of
post-radiation damage to cancerous cells occurring between
fractions of conventional radiation therapy. Depending on a
radiosurgery technique, the focus is supplied with doses with
different levels of inhomogeneity (higher with a gamma knife).
A high dose not only causes damage to tumorous cells, but also
to blood vessels that feed them.11,12
The linac system uses photon radiation. Many  ﬁelds of dif-
ferent angles are focused and dosage is precisely adjusted to
the volume of a tumour. The application of a multi-leaf colli-
mator reduces the need to use many  isocentres and enables a
decrease of dose to critical organs.13
In stereotactic radiation therapy, the therapeutic index
depends on the size of a tumour. The RTOG study on dose
escalation showed that a maximum tolerated dose is relative
of the size of a tumour. RTOG researchers determined maxi-
mum tolerated doses for particular tumour sizes. For tumours
of less than 20 mm,  it is 24 Gy; for tumours of 21–30 mm,  18 Gy;
for tumours of 31–40 mm,  15 Gy.14 The study by Mehta et al.
showed that local control decreases with the size of tumour.6
In patients with tumours of less than 2 cm3 in volume, the
complete response rate was 61% and the partial response rate
was 17%, for tumours of more  than 10 cm3 in volume, the com-
plete response rate was 10%, and the partial response rate was
40% (Table 2).
3.  Side  effects  of  radiosurgery
Radiosurgery is usually well tolerated and can be carried
out in an ambulatory setting. Therapy-related complications
are relatively rare and moderately severe. The advantage ofthe possibility to achieve total conservation of healthy tis-
sues owing to lower toxicity of radiation therapy. Nausea,
vomiting, alopecia and headaches are among most prevalent
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Table 2 – Retrospective studies on radiosurgery in treatment of brain metastases from primary lung cancer.
References Method NoPa NoM %NSCLC %SCLC Mean dose (Gy) %LC Mean survival
(months)
Kim et al.21 GN 77 115 100 0 16 85 10
Williams et al.22 Linac 30 45 47 0 16 100 7.9 NSCLC
8.4 other
Hoffman et al.23 GN 113 301 95 5 18 81 12
Sheehan et al.24 GN 273 627 100 0 17 84 7
Kong et al.28 GN 35 166 100 0 18.8 93 12a
Noel et al. [29] Linac 92 145 89 11 14 93 9
Chidel et al.31 Linac and GN Linac 73,
GN 62
218 48 0 18 ns. 7.9
RPA1 – 11.2
RPA2 and RPA3 –
6.9
Boosheng et al.25 Linac 41 ns. 100 0 20 83 9.3(RS)
10.6(RS + WBRT)
Zabel et al.30 Linac 86 110 100 0 20 96 4.5
Serizawa et al.27 GN 245 ns. 86 14 21 98% in NSCLC,
95% in SCLC
8.6 NSCLC
9.1 SCLC
Gerosa et al.26 GN 804 1307 57 0 20 93 13.5
NoP, number of patients; NoM, number of metastases; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; LC, local control; ns.,
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•not stated; KPS, Karnofsky performance status; CPD, controlled prim
a From diagnosis of metastasis.
ide symptoms, their intensity levels ranging from low to
oderate.15–17 Severe complications are divided by their
ccurrence into acute (early), subacute and late. Early compli-
ations (occurring within hours or days following treatment)
nvolve headaches, nausea, vomiting and seizures. Suba-
ute symptoms (occurring within ﬁrst six months) involve
edema, exacerbation of already existing neurological deﬁ-
iencies and seizures.15,18 Post-radiation necrosis may occur
s an early complication, but in most cases it is a late
omplication.15,16,18 Larger tumours and WBRT  relate to a
igher risk of complications.17,19
Early and late complications following radiosurgery of
rain metastases are relatively few.15,18,20 Acute reactions
nduced by brain oedema occur in 7–10% of patients within
wo weeks following treatment.
.  Aims
he aim of this study was to assess treatment results and
elected prognostic factors in patients with brain metastases
rom lung cancer treated with linac-based radiosurgery.
The following factors were subject to analysis:
 Age
 Gender
 Karnofsky performance status
 Primary disease status (controlled or uncontrolled)
 Local stage of primary disease
 Presence of extracranial metastases
 RPA class
 Histological type
 Type of metastases with regard to the time between the
occurrence and diagnosis of primary disease (premature,
synchronous, metachronous)sease; GN, Gamma knife.
• Number of brain metastases
• Location of brain metastases
• Dose in Gy
• Volume of the largest brain metastases
• Hb level
• Multiplicity of radiosurgical procedures
• WBRT  applied before or after radiosurgery
• Chemotherapy applied after radiosurgery
• Lung cancer surgery applied before or after radiosurgery
5.  Materials  and  methods
5.1.  Material
The study sample consisted of 83 patients with single or few
(2–4) intracranial metastases from lung cancer treated with
radiosurgery from February 2006 to September 2008. The study
was retrospective in nature.
All patients were treated with a linear-based radiosurgery
system (BrainLab) with immobilisation using a frameless
stereotactic thermoplastic mask. After mask ﬁxation, all
patients underwent computed tomography simulation. MRI
scans with T1 postgadolinium were fused to CT and used
to delineate the tumour with 2 mm margin. The dose was
prescribed to the 100% isodose line. Dose selection was deter-
mined by target volume, previous radiation, location and
nearby critical structures.
The age of the patients ranged from 40 to 82, the mean age
was 61. Males accounted for 69% of the study group.
The most prevalent histopathological type was adenocar-
cinoma occurring in 37 patients (47%), followed by squamous
cell carcinoma, with 20 patients (25%) affected. Patients with
non-small cell lung cancer accounted for 91% of cases (76
patients), while those with small cell lung cancer represented
22  reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 19–29
• Volume of the largest metastases
No statistical variation was found for the following factors:Fig. 1 – Karnofsky performance status.
9% (7 patients). The group of SCLC patients was small in our
study and radiosurgery in this group was used not as a ﬁrst line
treatment, but only when WBRT  was previously used (prophy-
lactically or for cure).
Most of the patients had locally advanced lung cancer at
diagnosis, 54% had stage IIIB and 18% stage IIIA cancers. The
presence of brain and extracranial metastases, which as well
known is a stage IV qualiﬁcation criterion, was not taken into
consideration while evaluating local stage of disease. The dis-
ease was in progression in as many  as 64% of patients being
subjected to radiosurgery.
Extracranial metastases occurred in 29 patients (35% of
cases), mostly to the bones, liver and adrenals. In 55% of cases
(46 patients), brain metastases occurred within two months
following the diagnosis of lung cancer (premature in 12% and
synchronous in 43%), metachronous metastases occurred in
45% of cases (37 patients).
Brain metastatic foci were treated mostly with doses of
18 Gy (37% of treated foci), 91% of patients were treated with
doses ranging from 14 to 24 Gy. The volume of the largest focus
was mostly up to 5 cm3 (33%), foci of up to 15 cm3 represented
82% of the total.
Single foci were managed in 69% of cases, two foci in 24%
of cases, three in 6% and four in 1% of cases. Metastases were
most commonly located in the parietal lobe (54%) and frontal
lobe (25%).
The most patients showed Karnofsky performance status
of 70 (59%) (Fig. 1). The largest proportion of them (57%) fell
into the RPA class II (Fig. 2).
The study involved a univariate and multivariate analy-
ses of selected survival prognostic factors and the time before
deterioration of neurological status. The univariate analysis
was performed using the Kaplan–Meier method. The statisti-
cal variation of the factors was assessed with the log-rank test
with signiﬁcance at p = 0.05. The multivariate analysis used the
Cox’s proportional hazards model with signiﬁcance at p = 0.05.6.  Results
Mean survival for the whole group of 83 patients was 7.8
months from radiosurgery and 11 months from the diagnosisFig. 2 – RPA classes.
of brain metastases. The survival probability from radio-
surgery and diagnosis of brain metastases for the whole group
is shown in Figs. 3 and 4.
6.1.  Univariate  analysis
Univariate analysis showed the following factors to have a
statistically signiﬁcant impact on patients’ survival:
• RPA class
• Karnofsky performance status
• Primary disease status (controlled or uncontrolled)
• Multiplicity of radiosurgical procedures
• Haemoglobin level
• Dose in Gy
• Presence of extracranial metastasesFig. 3 – Survival probability in relation to the time from RS.
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Table 3 – Prognostic factors whose statistically signiﬁcant impact was shown by the univariate analysis.
Factor Mean survival (months) 95% conﬁdence interval p value
RPA prognostic class <0.0001
RPA1 13.2 10.1–16.4
RPA2 8.2 6.7–9.7
RPA3 2.2 1.6–2.7
Karnofsky performance status 0.001
≥70 9.9 8.2–11.6
<70 5.7 3.8–7.7
Primary disease status 0.001
Controlled 10.7 8.1–13.3
Uncontrolled 5.9 4.6–7.1
Multiplicity of radiosurgery 0.002
Multiple RS 13.4 9.0–17.7
Single RS 6.9 5.6–8.1
Haemoglobin level 0.02
≥7 mmol/l 8.4 6.7–10.0
<7 mmol/l 4.7 2.0–7.4
Dose 0.03
>18 Gy 9.9 7.0–12.7
≤18 Gy 6.8 5.4–8.2
Presence of extracranial metastases 0.04
No 9.1 7.3–10.9
Yes 4.9 3.5–6.4
Volume of the largest brain metastasis
≤11 cm3 8.7
>11 cm3 6.1 
Fig. 4 – Survival probability in relation to the time to
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In our study group, we  showed a statistically signiﬁcant
impact of primary disease control on survival time (p < 0.001).
Mean survival in patients with controlled primary disease was
Table 4 – Prognostic factors whose statistically
signiﬁcant impact was not shown by the univariate
analysis.
Factor p value
Type of metastasis with regard to the time between
the occurrence and diagnosis of primary disease
0.17
WBRT applied before or after radiosurgery 0.18
Chemotherapy applied after radiosurgery 0.20
Lung cancer surgery 0.23
Histological type (adenocarcinoma vs. squamous
cell carcinoma)
0.24
Age 0.58
Main histological type (non-small cell vs. small cell
cancer)
0.65iagnosis of metastasis.
 Type of metastases with regard to the time between the
occurrence and diagnosis of primary disease (premature,
synchronous, metachronous)
 WBRT  applied before or after radiosurgery
 Chemotherapy applied after radiosurgery
 Lung cancer surgery
 Histological type (adenocarcinoma vs. squamous cell carci-
noma)
 Age
 Main histological type (non-small cell vs. small cell cancer)
 Number of brain metastases
 Local stage of primary disease
 Location of brain metastases
 Gender0.05
6.9–10.8
4.2–8.1
The results of the univariate analysis are summarised in
Tables 3 and 4.
The analysed sample showed a statistically signiﬁcant rela-
tionship between survival and RPA class (p < 0.0001). Mean
survival for the RPA class 1 was 13.2 months; for the RPA class
2, 8.2 months; and for the RPA class 3, 2.2 months. The diagram
of survival to RPA class relationship is shown in Fig. 5.
We  found a statistically signiﬁcant impact of Karnofsky
performance status (p = 0.001). Mean survival in patients with
KPS < 70 was 5.7 months, while in the group with KPS  > 70 it
was 9.9 months. The diagram of survival to KPS relationship
is shown in Fig. 6.Number of brain metastases 0.65
Local stage of primary disease 0.7
Location of brain metastasis 0.81
Gender 0.98
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Fig. 5 – Survival probability in relation to RPA class.
Fig. 6 – Diagram of survival in relation to Karnofsky
Fig. 8 – Survival probability in relation to RS multiplicity;
p = 0.002.performance status.
10.7 months, while in the group with uncontrolled primary
disease it was 5.9 months. The diagram of survival to primary
disease status is shown in Fig. 7.
In our study group, we showed a statistically signiﬁcant
impact of the multiplicity of radiosurgical treatments on
survival time (p < 0.002). Mean survival in patients who had
undergone a single radiosurgery was 6.9 months, while in the
Fig. 7 – Survival probability in relation to primary disease
status; p = 0.001.group treated with multiple treatments it was 13.4 months.
Radiosurgical treatment of the patient which was used more
than once was applied because of appearance of new lesion
during follow up. We never treated the tumour previously irra-
diated by radiosurgery. The diagram of survival to multiplicity
of treatment is shown in Fig. 8.
We  found a statistically signiﬁcant favourable effect of Hb
level ≥7 mmol/l on survival (p = 0.02). Mean survival in patients
with haemoglobin ≥7 mmol/l was 8.4 months vs. 4.7 months
in those with haemoglobin <7 mmol/l. The diagram of survival
to haemoglobin level is shown in Fig. 9.
We found a statistically signiﬁcant impact of dose on sur-
vival (p = 0.03). Mean survival in patients treated with dose
>18 Gy was 9.9 months vs. 6.8 months in those treated with
dose ≤18 Gy. The diagram of survival to dose is shown in
Fig. 10.
We also found a statistically signiﬁcant favourable effect
of the absence of extracranial metastases (p = 0.04). Mean
survival in patients without extracranial metastases was 9.1
months, while in the group with extracranial metastases it
was 4.9 months. The diagram of survival to occurrence of
extracranial metastases is shown in Fig. 11
Fig. 9 – Survival probability in relation to haemoglobin
level; p = 0.02.
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Fig. 10 – Survival probability in relation to dose; p = 0.03.
Fig. 11 – Survival probability in relation to the presence of
extracranial metastases; p = 0.04.
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Fig. 12 – Survival probability in relation to the volume of
the largest metastasis; p = 0.05.
Fig. 13 – Probability of prolonging the time to brain local
radiosurgical treatment. Death risk in patients with KPS < 70
was 10 times higher than in those with KPS > 70. Death risk inIn our study group, we  showed a statistically signiﬁcant
avourable impact of the largest metastatic focus <11 cm3 on
urvival (p < 0.05). Mean survival in patients in whom the vol-
me  of the largest metastases was less than or equal to 11 cm3
as 8.7 months vs. 6.1 months in patients in whom the volume
f the largest metastases was more  than 11 cm3. The diagram
f survival to the largest metastases volume is shown in Fig. 12.
It was found that dose >18 Gy is a signiﬁcant factor inﬂu-
ncing improvement of local control in the brain (p = 0.02),
s shown in Fig. 13. The mean time to progression after the
dministration of dose >18 Gy was 7.2 months vs. 5.7 months
fter a dose <18 Gy. A probability of a six-month local brain
rogression-free survival was 90% in the case of a dose >18 Gy
s. 80% for a dose <18 Gy.
A mean time to progression of controlled focus or emer-
ence of new metastatic foci was 7.9 months. That time is
imilar to the mean time to deterioration of neurological
ymptoms, that is 7.1 months. In our sample, the mitigation
r stabilisation of neurological symptoms was achieved in 94%
f patients. This effect carried on for an average of 7.1 months.progression in relation to dose; p = 0.02.
Notably, no statistically signiﬁcant relationship was found
between age and survival time (p = 0.58). In our study, patients
aged >65 account for 34% of the total sample.
6.2.  Multivariate  analysis
Due to the complexity of the RPA classiﬁcation, two multivari-
ate analyses were made under the study. The ﬁrst multivariate
analysis comprised all factors whose statistical signiﬁcance
was proved in the univariate analysis, except for assignment
to a particular RPA class. The other multivariate analysis
reﬂected the assignment to a RPA class and all factors except
those covered by the RPA classiﬁcation. The multivariate
analysis used the Cox’s proportional hazards model with sig-
niﬁcance at p = 0.05. Results of the multivariate are shown
in Table 5. The ﬁrst multivariate analysis showed a positive
statistically signiﬁcant impact on survival of the following fac-
tors: KPS > 70, lack of extracranial metastases, multiplicity ofpatients affected with extracranial metastases was 1.9 times
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Table 5 – Multivariate analysis results.
Factor Analysis without RPA Analysis with RPA
Risk of death (CIa) p value Risk of death (CIa) p value
RPA prognostic class Not included
RPA1 1
RPA2 1.7 (0.9–3.6) 0.12
RPA3 15.1 (6.1–37.6) <0.0001
Karnofsky performance status Not included
≥70 1
<70 10.0 (5.1–19.7) <0.0001
Presence of extracranial metastases Not included
No 1
Yes 1.9 (1.1–3.2) 0.02
Multiplicity of RS
Multiple RS 1 1
Single RS 3.1 (1.2–8.3) 0.03 2.9 (1.1–7.9) 0.04
Haemoglobin level
≥7 mmol/l 1 1
<7 mmol/l 1.6 (0.9–3.0) 0.13 1.73 (0.9–3.2) 0.09
Volume of the largest brain metastasis
≤11 cm3 1 1
>11 cm3 1.4 (0.8–2.4) 0.23 1.3 (0.7–2.6)
Primary disease status NOT INCLUDED
Controlled 1
Uncontrolled 1.5 (0.8–2.8) 0.26
Dose
>18 Gy 1 1
≤18 Gy 1.2 (0.6–2.4) 
a 95% conﬁdence interval.
higher than in those free of extracranial metastases. Death
risk in patients treated with single radiosurgery was 3.1 times
higher than in those treated with multiple radiosurgery treat-
ments. The other multivariate analysis showed a statistically
signiﬁcant impact on survival of the following factors: assign-
ment to the RPA class 1 as opposed to the RPA class 3 and
multiplicity of radiosurgical treatment. Death risk in patients
of the RPA class 3 was 15.1 times higher than in those of
the RPA class 1. Death risk in patients treated with single
radiosurgery was 2.9 times higher than in those treated with
multiple radiosurgery.
7.  Discussion
Mean survival in patients with brain metastases from lung
cancer treated with radiosurgery, as reported in literature,
ranges from 4.5 to 13.5 months.21–31 Those data apply to
patients treated with both a gamma knife and accelerator.
Some studies, where higher survival times were achieved,
tended to assume certain exclusion criteria.21–23,25,26,28,29,31
For example, patients with low Karnofsky performance sta-
tus were excluded. Our study covered all patients who had
undergone radiosurgery in the above indicated period. Our
mean survival times differed substantially from survival times
of patients untreated (approx. 1 month) and of those treated
with steroids (approx. 2 months)32 or WBRT  alone (approx. 3–5
months).7,33 Rodrigus et al.34 reported results for 250 patients
with brain metastases from primary lung cancer treated with
WBRT  in 1993–1998. They reported a mean survival time of
only 3.1 months. Also in Fernandez et al. study40 median0.55 1.1 (0.5–2.3) 0.93
survival time for group of 39 patients (14 with lung cancer)
treated with WBRT  was only 3 months. Those results varied
considerably from mean survival times in our study sample
and other investigations of radiosurgical treatment. The out-
come of radiosurgery, on the other hand, is similar to that of
surgery. Wron´ski et al.1 published results for surgery of brain
metastases from primary lung cancer in 231 patients managed
in 1976–1991. Mean survival time in that group was 11 months,
and post-operative mortality rate was 3%. In that study, 61%
of patients exhibited KPS > 80.
Statistically signiﬁcant relationship between survival and
RPA class (p < 0.0001) which was found in our study was also
demonstrated by other authors.
Mean survivals for particular RPA classes are different than
those reported by Gaspar. They are higher in the RPA classes I
and II and comparable in the RPA class III. Therefore, a conclu-
sion may be drawn that radiosurgical treatment is superior to
other types of therapy only for patients representing the RPA
classes I and II, i.e. those with KPS > 70. Mean survival was 13.2
months (7.1 months in Gaspar’s study) for the RPA class I; 8.2
months (4.2 months in Gaspar’s study) for the RPA class II; and
2.2 months (2.3 months in Gaspar’s study) for the RPA class III.
The results demonstrate beneﬁt of radiosurgery in properly
selected patients.
Comparably to other authors’ studies,24,27,29,31 we  found a
statistically signiﬁcant impact of Karnofsky performance sta-
tus (p = 0.001). Mean survival in patients with KPS < 70 was 5.7
months, while in the group with KPS > 70 it was 9.9 months.
Hoffman et al. reported a mean survival time of 9.3 in the
KPS 50–60 group, 7 months in the KPS 70–80 group and 13.9
months in the KPS 90–100 group.
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This correlation accounts for the difference in the mean
urvival between particular authors’ reports as arising from
ifferent proportions of patients representing speciﬁc perfor-
ance statuses. A relatively high proportion of patients in our
ample (25%) had KPS < 70, which certainly affected the mean
urvival time being somewhat lower than in other studies.
In our study group a statistically signiﬁcant impact of
rimary disease control on survival time (p < 0.001) was
emonstrated. Mean survival in patients with controlled pri-
ary  disease was 10.7 months, while in the group with
ncontrolled primary disease it was 5.9 months. The impact
as also been proved in many  other studies.21,23,24,27,29–31
heehan et al. reported a mean survival of 16 months in a
ontrolled primary disease group vs. 7 months in an uncon-
rolled group. In the study by Kim et al., the values are 12 and
 months, respectively.
In our study group, we  showed a statistically signiﬁcant
mpact of the multiplicity of radiosurgical treatments on sur-
ival time (p < 0.002). Multiplicity of radiosurgical treatments
eans treatment by radiosurgery new lesion found during
ollow up. This impact may be due to the fact that most of
he patients subjected to multiple radiosurgery had initially
een qualiﬁed to better RPA classes. Consequent longer sur-
ival enabled the patients to be observed longer and treated
ith radiosurgery as a life-saving treatment in cases of brain
rogression (management of a new metastatic focus).
Statistically signiﬁcant favourable effect of Hb level
7 mmol/l on survival (p = 0.02) is likely to be due to the fact
hat the level of haemoglobin affects a patient’s general health
tatus and tumour oxidation, thus making it more  sensitive to
adiation.
Statistically signiﬁcant impact of dose on survival (p = 0.03)
hich was found in our study was not conﬁrmed in studies of
ther authors.21,23,30
Statistically signiﬁcant favourable effect of the absence
f extracranial metastases (p = 0.04) which was found in our
tudy was also reported by Hoffman et al.23 who showed that
 mean survival in patients without extracranial metastases
as 13.9 months vs. 8.6 months in patients with extracranial
etastases.
The impact of dose on local brain progression-free survival
hich was found in our study was also demonstrated by Hoff-
an  et al.23 In this study, the probability of a six-month local
rain progression-free survival was 95% in the case of a dose
18 Gy, 82% for a dose between 15 Gy and 18 Gy, 28% for a dose
15 Gy.This impact seems to be obvious because the dose is
onnected with tumour volume.
A mean time to progression of controlled focus or emer-
ence of new metastatic foci was 7.9 months. That time is
imilar to the mean time to deterioration of neurological
ymptoms, that is 7.1 months. Mitigation or stabilisation of
ymptoms is the main objective behind treatment of brain
etastases, leading to the improvement of the quality of life.
n our sample, the mitigation or stabilisation of neurological
ymptoms was achieved in 94% of patients. This effect carried
n for an average of 7.1 months. This result is similar to the
ean survival, meaning that most of the patients, owing to
he treatment, did not suffer from deterioration of neurologi-
al symptoms. The result is comparable to those reported by
ther authors. In the study by Zabel et al.,30 an improvementiotherapy 1 9 ( 2 0 1 4 ) 19–29 27
or stabilisation was found in 95% of patients in a retrospec-
tive analysis of 86 patients with brain metastases from NSCLC
treated with radiosurgery using an accelerator.
No statistically signiﬁcant relationship was found in our
study between age and survival time (p = 0.58). It is very inter-
esting and useful outcome.
Life expectancy constantly rises both in the Western
countries and Poland. Older people are exposed to an
increased risk of cancer. Cancer incidence grows with age.
The incidence of brain metastases is also correlated with age.
Around 15% of patients with brain metastases from various
types of cancer are over 65 years of age.4 Older patients are
often treated with less radical methods, compared to younger
patients, due to a commonly shared belief that their treat-
ment tolerance may be lower and expected survival time,
shorter. Although 50% of cancers occur in patients aged over
70,35 the knowledge on treatment tolerance in older people is
limited, as such patients tend to be excluded from prospective
randomised trials due to their age or concomitant diseases.
Therefore, data derived from retrospective studies are of great
importance.
Noel et al.,36 responding to this need, carried out a ret-
rospective analysis of 117 patients aged >65 with brain
metastases treated with radiosurgery using accelerators (45%
of the study group consisted of lung cancer patients). Mean
survival in that group was 8 months, which is more  than in
the RTOG 9508 study (6.5 months) where patients over 65 years
of age represented only 35% of the study sample. Local con-
trol was 95%. This treatment was well tolerated. This leads to
a conclusion that patient’s age should not be a disqualifying
criterion for radiosurgical treatment.
Opposite to other authors we did not proved the female
gender and histological type of adenocarcinoma to be
independent favourable prognostic factors in lung cancer
patients.39
8.  Treatment  tolerance
Radiosurgery is well tolerated by patients. Only 5% of our study
group showed exacerbation of any of earlier occurring neuro-
logical symptoms within the ﬁrst month. Four patients (5%)
had to be operated for foci that had earlier been given radio-
surgical treatment. It is hard to establish, however, whether
the increase in tumour volume producing serious clinical
symptoms was caused by post-radiation necrosis or tumour
progression due to the loss of local control. Patients in our
study group did not complain about difﬁculties in memorising
or deterioration of cognitive abilities, which is quite a frequent
(occurring in 11% of cases) symptom following WBRT.37,38
9.  Conclusion
1. Radiosurgery performed with a linear accelerator is a safe
and effective treatment modality for brain metastases from
primary lung cancer. It allows a radical treatment of metas-
tases even in the critical structures of the brain, such as the
brain stem, which are inaccessible for surgery, and treat-
ment of old patients.
nd ra
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2. Survivals achieved owing to radiosurgery were much longer
than those following whole brain radiation therapy and
comparable to those reported for patients treated with
surgery. We  demonstrated a clear favourable effect of
radiosurgery on survival following radiosurgery applied to
the RPA1 and RPA2 patients, but not the RPA3 patients
(with Karnofsky performance status <70), for whom symp-
tomatic treatment should be considered.
3. Our study did not ﬁnd a statistically signiﬁcant relation-
ship between age and treatment outcome. Age should not
be a reason for disqualifying patients from radiosurgical
treatment.
4. Our results proved that Karnofsky performance status is
the factor of the strongest impact on prognosis. The mul-
tivariate analysis conﬁrmed after the univariate analysis
that the following factors have a statistically signiﬁcant
impact on patients’ survival:
• Karnofsky performance status >70,
• Assignment to the RPA class 1 as opposed to the RPA class
3,
• Absence of extracranial metastases,
• Multiplicity of radiosurgical procedures (treatment of new
lesions)
5. The factors whose statistically signiﬁcant positive impact
on survival was shown in the univariate analysis, but not
conﬁrmed by the multivariate analysis, include:
• Controlled primary disease,
• Haemoglobin level >7 mmol/1,
• Dose >18 Gy,
• Volume of the largest brain metastases ≤11 cm3.
The multivariate analysis did not conﬁrm a prognostic
value of those factors probably due to their impact on
patient’s performance status.
6. Dose >18 Gy is a signiﬁcant factor in improvement of brain
local control.
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